Hernández-Jiménez C, Olmos-Zúñiga JR, Jasso-Victoria R, Gaxiola-Gaxiola M, Baltazares-Lipp M, Sánchez-Arrozena LS, Gutiérrez-González LH

Idioma: Español
Referencias bibliográficas: 48
Paginas: 452-460
Archivo PDF: 439.84 Kb.

RESUMEN

Introducción. El daño pulmonar agudo (ALI) es una patología caracterizada por lesión de la membrana alvéolo-capilar que origina un proceso inflamatorio tanto local como sistémico. La endotelina (ET) es una proteína que actúa como modulador inmune, aunque un incremento en su síntesis puede contribuir al daño pulmonar. Objetivo. Evaluar si el propofol atenúa las alteraciones hemodinámicas, gasométricas, microscópicas, inmuno-histoquímicas y de concentración plasmática de ET-1 en un modelo experimental de daño pulmonar agudo inducido por ácido oleico (OA). Material y métodos. Los perros mestizos incluidos en el estudio se dividieron en tres grupos de estudio: grupo I testigo, grupo II ALI producido con OA sin tratamiento y grupo III pretratamiento con propofol y ALI inducido con OA. Resultados. Todos los animales sobrevivieron al tiempo de estudio. Los hallazgos hemodinámicos, gasométricos y gravimétricos revelaron que los grupos II y III desarrollaron ALI. Sin embargo, el grupo III mostró menor infiltrado inflamatorio y expresión de ET-1 en tejido pulmonar. Conclusiones. El pretratamiento con propofol en un modelo canino de ALI provocado por OA indica que el fármaco presenta acción antiinflamatoria, con un potencial papel terapéutico contra la progresión de la inflamación y daño pulmonar.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Schuster DP. ARDS: Clinical lessons from the oleic acid model of acute lung injury. Am J Resp Crit Care Med 1994; 149: 245-60.

2. Rubenfeld GD, Caldwell E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2000; 342: 1301-8.

3. Olivar LV, Rivera VR, Chávez LA. Criterios diagnósticos de síndrome de dificultad respiratoria aguda en México. Bol Med Hosp Infant Mex 2000; 57(5): 263-69.

4. Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of Acute Lung Injury. Pulmonary Pharmacology & Therapeutics 2002; 15: 83-95.

5. Guimaraes CL. Endothelin ETB receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice. Clinical Science 2002; 103(Suppl. 48): 34OS-344S.

6. Motohiro A, Furukawa T, Yasumoto K, et al. Mechanisms envolved in acute lung edema induced in dogs by oleic acid. Eur Surg Res 1986; 18: 50-57.

7. Lim SC, Adams AB, Simonson DA, et al. Transient hemodynamic effects of recruitment maneuvers in three experimental models of acute lung injury. Crit Care Med 2004; 32: 2378-84.

8. Fagan KA, McMurtry IF, Rodean DM. Role of endothelin-1 in lung disease. Respir Res 2001; 2: 90-101.

9. Simmet T, Pritzie S, Thelen KI, Peskar BA. Release of endothelin in the oleic acid-induced respiratory distress syndrome in rats. Eur J Pharmacol 1992; 211: 319-22.

10. Langleben D, Demarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin 1 in acute lung injury and the adult respiratory distress syndrome in rats. Am Rev Respir Dis 1993; 148: 1646-50.

11. Booke M. The effects of propofol on hemodynamics and renal blood flow in healthy and septic sheep. Anesth Analg 1996; 82: 738-43.

12. Hofbauer R, Frass M, Salfinger H, et al. Propofol reduces the migration of human leucocytes trough endotelial cell monolayers. Critical care Medicine 1999; 27: 1843-47.

13. Mikawa K, Akamatsu H, Nishina K, et al. Propofol inhibits human neutrophil functions. Anesthesia Analgesia 1998; 87: 695-700.

14. Aoki H, Mizobe T, Nozuchi S, Hiramatsu N. In vivo and in vitro studies of inhibitory effect of propofol on human platelet aggregation. Anesthesiology 1998; 88(2): 362-70.

15. Taniguchi T, Kanakura H, Yamamoto K. Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med 2000; 28: 1101-06.

16. Taniguchi T, Kanakura H, Yamamoto K. Effects of postreatment with propofol on mortality and cytokine responses to en dotoxin-induced shock in rats. Crit Care Med 2002; 30: 904- 07.

17. Galley HF, Dubbels AM, Webster NR. The effect of midazolam and propofol on interleucine 8 from human polymorphonuclear leukocytes. Anesthesiology 1988; 88: 362-70.

18. Irina VB, Visintine DJ, Gunnerson HB, Paisansathan Ch, Baughman VL, et al. Propofol attenuates lung endothelial injury induced by ischemia-reperfusion and oxidative stress. Anesth Analg 2005; 100: 929-36.

19. De la Cruz JP, Sedeño G, Carmona JA, Sánchez de la Cuesta F. The in vitro effects of propofol on tisular oxidative stress in the rat. Anesth Analg 1998; 87: 1141-6.

20. Petros AJ, Bogle RG, Pearson J. Propofol stimulates nitric oxide release from cultured porcine aortic endothelial cells. Br. J Pharmacol 1993; 109: 6-7.

21. Takao Y, Mikawa K, Nishina K, Obara H. Attenuation of acute lung injury with propofol in endotoxemia. Anesth Analg 2005; 100: 810-6.

22. Chu CH, Liu DD, Hsu YH, Lee KC, Chen IH. Propofol exerts protective effects on the acute lung injury induced by endotoxin in rats. Pulmonary Pharmacol & Therapeutics 2007; 20(5): 503-12.

23. Chen Hsing I, Nan-Kuang Hsieh, Shang Jyh Kao, et al. Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats. Crit Care Med 2008; 36(4): 1214-21.

24. Especificaciones técnicas para la producción, cuidado y uso de animales de laboratorio. Diario Oficial de la Federación de los Estados Unidos Mexicanos. AFIA 6 Dic de 1999.

25. National Institutes of Health U.S.A. Guía Para el Cuidado y Uso de Los Animales de Laboratorio. Department of Health and Human Services, Public Health Service, National Institutes of Health U.S.A. Edición Mexicana Auspiciada por la Academia Nacional de Medicina. México, D.F. 2002.

26. Hernández JC, Jasso VR, Olmos ZR, Villalba CJ, Gaxiola GM, Sotres VA, et al. Modelo Experimental canino de daño pulmonar agudo producido con ácido oleico: estableciendo un modelo de trabajo. Rev Invest Clin 2010; 62(3): 222-30.

27. Hyun KS, Jeong II Choi, Jong Tae Park. Effects of Propofol on Endotoxin-induced Acute Lung Injury in Rabbit. J Korean Med Sci 2004; 19: 55-61.

28. Bernard GR, Artigas A, Brigham KL, Carlet J, Hudson L, et al. The American–European consensus conference on ARDS: definitions, mechanism, relevant outcomes and clinical coordination. Am J Resp Crit Care Med 1994; 149: 818-24.

29. Matute-Bello G, Frevert WC, Martin TR. Animals models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008; 295: L379-L399.

30. Beilman G. Pathogenesis of oleic-induced lung injury in the rat: distribution of oleic acid during injury and early endothelial cell changes. Lipids 1995; 30: 817-23.

31. Eiermann G, Dickey B, Thrall R. Polymorphonuclear leukocyte participation in acute oleic-acid-induced lung injury. Am Rev Resp Dis 1983; 128: 845-50.

32. Hofman W, Ehrhart I. Permeability edema in dog lung depleted of blood components. J Appl Physiol 1984; 57: 147-53.

33. De la Cruz JP, Páez MV, Carmona JA. Propofol inhibits in vitro platelet aggregation in human whole blood. Anesth Analg 1997; 84: 919-24.

34. De la Cruz JP, Páez MV, Carmona JA. Antiplatelet effect of the anesthetic drug propofol: influence of red cells and leucocytes. Br J Pharmacol 1999; 128: 1538-44.

35. Miyazawa T, Nakagawa H, Hiramoto M, Arita K, Hiramoto T, Nishida O. Ultrastructural study on the alveolar-capillary injury with pulmonary edema induced by oleic acid in dogs. Hiroshima J Med Sci 1981; 30: 183-90.

36. Wang HM, Bodenstein M, Markstaller K. Overview of the Pathology of Three widely used animals models of acute lung Injury. Eur Surg Res 2008; 40: 305-16.

37. Hyun KS, Jeong II Choi, Jong Tae Park. Effects of propofol on endotoxin-induced acute lung injury in rabbit. J Korean Med Sci 2004; 19: 55-61.

38. Michael JR, Markewitz BA. Endothelins and the lung. Am J Resp Crit Care Med 1996; 154: 555-81.

39. Simmet T, Pritzie S, Thelen KI, Peskar BA. Release of endothelin in the oleic acid-induced respiratory distress syndrome in rats. Eur J Pharmacol 1992; 211: 319-22.

40. Langleben D, Demarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin 1 in acute lung injury and the adult respiratory distress syndrome in rats. Am Rev Respir Dis 1993; 148: 1646-50.

41. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaka K. Circulating endothelin-1 concentrations in acute respiratory failure. Chest 1993; 104: 476-80.

42. Albertine KH, Wang ZM, Michael JR. Expression of endotelial nitric oxide synthase, inducible nitric oxide synthase, and endothelin- 1 in lungs of subjects who died with ARDS. Chest 1999; 111: 101S-102S.

43. Fagan AK, McMurtry FI, Rodman MD. Role of endothelin-1 in Lung disease. Resp Res 2001; 2: 90-101.

44. Hsing CH, Lin MC, Choi PC, Huang WC, Kai JI, Tsai CC, et al. Anesthetic propofol reduce endotoxic inflammation by inhibiting reactive oxygen specien-regulated AKT/IKKβ/NF-κB signaling. Plos One 2011; 6(3): e17598.

45. Song XM, Wang YL, Li JG, Wang CY, Zhou Q. Effects of propofol on pro-inflammatory cytokines and nuclear factor kappa B during polymicrobial sepsis in rats. Mol Biol Rep 2009; 36: 2345-51.

46. Chiu WT, Lim YL, Chou CW, Chen RM. Propofol inhibits lipoteichoic acid-induced iNOS gene expression in macrophages possibly through down-regulation of toll-like receptor 2-mediated activation of Raf-MEK 1/2-IKK-NFkappaB. Chem Biol Interact 2009; 181: 430-39.

47. Barnes PJ. Endothelins and pulmonary diseases. J Appl Physiol 1994; 77: 1051-9.

48. Guembe L, Villaro A. Immunohistochemical mapping of endothelin in the developing and adult mouse lung. J Histochemistry & cytochemistry 2001; 49(10): 1301-09.